Stockholders’ Equity (Details) - USD ($) |
1 Months Ended | 12 Months Ended | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Apr. 12, 2021 |
Feb. 09, 2021 |
Sep. 29, 2022 |
Sep. 28, 2022 |
Sep. 26, 2022 |
Aug. 29, 2022 |
Mar. 31, 2022 |
Jan. 27, 2022 |
Dec. 29, 2021 |
Jan. 18, 2021 |
Apr. 17, 2020 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Nov. 30, 2019 |
Apr. 30, 2013 |
|
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||
Shares authorized | 505,000,000 | ||||||||||||||
Common stock, shares authorized | 500,000,000 | 500,000,000 | |||||||||||||
Preferred stock, shares authorized | 5,000,000 | 5,000,000 | |||||||||||||
Designated shares of preferred stock | 4,280 | ||||||||||||||
Preferred stock, par value (in Dollars per share) | $ 0.0001 | $ 0.0001 | |||||||||||||
Series C convertible preferred stock | 4,049 | 227 | |||||||||||||
Warrants term | 5 years | ||||||||||||||
Exercise price (in Dollars per share) | $ 15 | ||||||||||||||
Preferred stock conversion, description | The Series C Convertible preferred stock and the February Warrants each contain a beneficial ownership limitation that restricts each of the investor’s ability to exercise the February Warrants and convert the Series C Convertible preferred stock such that the number of shares of the Company common stock held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor, 9.99%) of the Company’s then issued and outstanding shares of common stock. | ||||||||||||||
Subsequent financing, percentage | 50.00% | ||||||||||||||
Liquidity damage, description | If the Company fails to file the Registration Statement or have it declared effective by the dates set forth above, amongst other things, the Company will be obligated to pay the investors damages in the amount of 1% of their subscription amount, per month, until such events are satisfied. | ||||||||||||||
Placement agent warrants, description | In addition, pursuant to the terms of the offering, the Company issued Bradley Woods & Co, Ltd. and Katalyst Securities LLC warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 57,013 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment. | ||||||||||||||
Convertible preferred stock into common stock, description | the Company notified holders of its Series C Convertible Preferred Stock of its election to force the conversion to 4,049 shares of its Series C Convertible Preferred Stock into 269,900 shares of the Company’s common stock. As of December 31, 2021, there were 227 shares of the Company’s Series Convertible Preferred Stock issued and outstanding | ||||||||||||||
Public offering shares | 1,000,000 | ||||||||||||||
Public offering price per share (in Dollars per share) | $ 5 | ||||||||||||||
Purchase of additional shares | 150,000 | 150,000 | |||||||||||||
Offering issued, description | the Company closed the Offering and issued the Shares for aggregate net proceeds of $4,940,948, after deducting underwriting discounts and commissions and offering expenses. The Company intends to use the net proceeds from the offering for research and development activities, sales and marketing, general working capital purposes, potential acquisitions of other companies, products or technologies, and to repay certain indebtedness. Concurrently with the closing of the Offering, the Company also issued warrants to purchase an aggregate of up to 57,500 shares of its common stock to the representative of the Underwriters or its designees, at an exercise price of $6.25 per share (the “Representative’s Warrants”). The Representative’s Warrants are exercisable beginning on March 25, 2023, and expire on September 26, 2027, pursuant to the terms and conditions of the Representative’s Warrants. | concurrently with the closing of the Offering as discussed above, the Company also issued warrants to purchase an aggregate of up to 57,500 shares of its common stock to the representative of the Underwriters or its designees, at an exercise price of $6.25 per share (the “Representative’s Warrants”). The Representative’s Warrants are exercisable beginning on March 25, 2023, and expire on September 26, 2027, pursuant to the terms and conditions of the Representative’s Warrants. | |||||||||||||
Restricted common shares | 20,000 | ||||||||||||||
Common share value (in Dollars) | $ 135,100 | ||||||||||||||
Price per common shares (in Dollars per share) | $ 6.755 | ||||||||||||||
Professional fees (in Dollars) | $ 45,033 | ||||||||||||||
Prepaid expenses (in Dollars) | $ 90,067 | ||||||||||||||
Expired term | Dec. 26, 2026 | ||||||||||||||
Fair value of unvested stock option | 152,619 | ||||||||||||||
Employment agreement, description | pursuant to an Employment Agreement (see Note 9), an aggregate of 16,000 incentive stock options were issued under the 2020 Plan, to Dr. Kou, exercisable at $10.00 per share and expires on January 31, 2032. The stock options vest as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023. | ||||||||||||||
Purchase agreement, description | the Company entered into pursuant to securities purchase agreements with certain investors pursuant to which it sold warrants to purchase up to 285,067 shares of the Company’s common stock and 4,276 shares of the Company’s Series C Convertible preferred stock. The February Warrants are exercisable for a period of five years from the date of issuance at an exercise price of $15.00 per share, subject to adjustment. If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. In addition, pursuant to the terms of the offering, the Company issued the Placement Agent Warrants to purchase up to an aggregate of 57,013 shares of common stock to its placement agents, or 10% of the shares of common stock issuable upon conversion of the Series C preferred stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment (see Series C Convertible Preferred Stock Financing above). Such warrants issued to various investors and to the placement agents were recorded as additional paid in capital with an offsetting debit applied against additional paid in capital, thus these warrants have no further accounting effect within the equity section. | ||||||||||||||
Placement Agent Warrants [Member] | |||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||
Risk free interest rate | 0.50% | ||||||||||||||
Expected dividend yield | 0.00% | ||||||||||||||
Expected term | 5 years | ||||||||||||||
Expected volatility | 169.00% | ||||||||||||||
Aggregate grant date fair value of placement agent warrants (in Dollars) | $ 1,106,000 | ||||||||||||||
Warrant [Member] | |||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||
Warrants term | 5 years | ||||||||||||||
Exercise price (in Dollars per share) | $ 10 | ||||||||||||||
Risk free interest rate | 0.46% | ||||||||||||||
Expected term | 5 years | ||||||||||||||
Expected volatility | 169.00% | ||||||||||||||
Granted warrants to purchase shares | 5,000 | ||||||||||||||
Grant date price per warrant (in Dollars per share) | $ 16.5 | ||||||||||||||
Warrant value (in Dollars) | $ 83,728 | ||||||||||||||
Stock price (in Dollars per share) | $ 17.5 | ||||||||||||||
Stock-based Compensation (in Dollars) | $ 83,728 | ||||||||||||||
Series A Preferred Stock [Member] | |||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||
Preferred stock, shares authorized | 1,000,000 | 1,000,000 | |||||||||||||
Designated shares of preferred stock | 1,000,000 | ||||||||||||||
Share issued | |||||||||||||||
Share outstanding | |||||||||||||||
Preferred stock, par value (in Dollars per share) | $ 0.0001 | $ 0.0001 | |||||||||||||
Series B Convertible Preferred Stock [Member] | |||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||
Preferred stock, shares authorized | 2,000 | 2,000 | |||||||||||||
Designated shares of preferred stock | 2,000 | ||||||||||||||
Share issued | |||||||||||||||
Share outstanding | |||||||||||||||
Preferred stock, par value (in Dollars per share) | $ 0.0001 | $ 0.0001 | |||||||||||||
Series C Convertible Preferred Stock [Member] | |||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||
Designated shares of preferred stock | 4,280 | ||||||||||||||
Preferred stock, par value (in Dollars per share) | $ 0.0001 | ||||||||||||||
Preferred stock, stated value (in Dollars) | $ 1,000 | ||||||||||||||
Convertible preferred stock, description | A holder of Series C Convertible preferred stock may not convert any portion of the Series C Convertible preferred stock to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares of the Company’s common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%. | ||||||||||||||
Deemed dividend (in Dollars) | $ 1,403,997 | ||||||||||||||
Series C Conversion Price [Member] | |||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||
Conversion price per share (in Dollars per share) | $ 15 | ||||||||||||||
Series C Purchase Agreements [Member] | |||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||
Sale of aggregate shares | 4,276 | ||||||||||||||
Warrant to purchase shares | 285,067 | ||||||||||||||
Gross proceeds (in Dollars) | $ 4,276,000 | ||||||||||||||
Offering expenses (in Dollars) | $ 481,898 | ||||||||||||||
Conversion of Series C Convertible Preferred Stock into Common Stock [Member] | |||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||
Remaining shares | 227 | ||||||||||||||
Series C Preferred Stock [Member] | |||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||
Preferred stock, shares authorized | 4,280 | 4,280 | |||||||||||||
Share issued | 0 | 227 | |||||||||||||
Share outstanding | 0 | 227 | |||||||||||||
Preferred stock, par value (in Dollars per share) | $ 0.0001 | $ 0.0001 | |||||||||||||
Convertible preferred stock | 227 | ||||||||||||||
Convertible common stock | 15,167 | ||||||||||||||
Stock Options [Member] | |||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||
Deferred compensation (in Dollars) | $ 80,790 | ||||||||||||||
Issuance of deferred compensation balance (in Dollars) | 14,125 | ||||||||||||||
Board Granted [Member] | |||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||
Exercise price (in Dollars per share) | $ 7.3 | ||||||||||||||
Risk free interest rate | 0.75% | ||||||||||||||
Expected term | 2 years | ||||||||||||||
Expected volatility | 0.00% | ||||||||||||||
Aggregate of incentive stock options | 6,849 | ||||||||||||||
Stock option value (in Dollars) | $ 30,224 | ||||||||||||||
Expected volatility | 115.00% | ||||||||||||||
Fair value of unvested stock option | 30,224 | ||||||||||||||
Deferred compensation (in Dollars) | 30,224 | ||||||||||||||
Issuance of deferred compensation balance (in Dollars) | $ 0 | ||||||||||||||
Omnibus Equity Incentive Plan [Member] | |||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||
Shares of common stock reserved and avail for issuance | 170,000 | ||||||||||||||
Incentive Stock Option [Member] | |||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||
Risk free interest rate | 1.18% | ||||||||||||||
Expected dividend yield | 0.00% | ||||||||||||||
Expected term | 2 years | ||||||||||||||
Expected volatility | 117.00% | ||||||||||||||
Stock option | 16,000 | ||||||||||||||
Fair value of stock option (in Dollars) | $ 94,915 | ||||||||||||||
Fair value of the unvested stock options (in Dollars) | $ 94,915 |